JP2008526805A - ベータ−２アドレナリン作動薬のケイヒ酸塩 - Google Patents

ベータ−２アドレナリン作動薬のケイヒ酸塩 Download PDF

Info

Publication number
JP2008526805A
JP2008526805A JP2007549866A JP2007549866A JP2008526805A JP 2008526805 A JP2008526805 A JP 2008526805A JP 2007549866 A JP2007549866 A JP 2007549866A JP 2007549866 A JP2007549866 A JP 2007549866A JP 2008526805 A JP2008526805 A JP 2008526805A
Authority
JP
Japan
Prior art keywords
hydroxy
methyl
phenyl
amino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007549866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526805A5 (OSRAM
Inventor
バーノン，ロイス，エリザベス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500513A external-priority patent/GB0500513D0/en
Priority claimed from GB0514199A external-priority patent/GB0514199D0/en
Priority claimed from GB0514200A external-priority patent/GB0514200D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2008526805A publication Critical patent/JP2008526805A/ja
Publication of JP2008526805A5 publication Critical patent/JP2008526805A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Golf Clubs (AREA)
  • Quinoline Compounds (AREA)
JP2007549866A 2005-01-11 2006-01-09 ベータ−２アドレナリン作動薬のケイヒ酸塩 Pending JP2008526805A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64284405P 2005-01-11 2005-01-11
GB0500513A GB0500513D0 (en) 2005-01-11 2005-01-11 Novel compounds
GB0514199A GB0514199D0 (en) 2005-07-11 2005-07-11 Novel compounds
GB0514200A GB0514200D0 (en) 2005-07-11 2005-07-11 Novel compounds
PCT/EP2006/000141 WO2006074897A1 (en) 2005-01-11 2006-01-09 Cinnamate salts of a beta-2 adrenergic agonist

Publications (2)

Publication Number Publication Date
JP2008526805A true JP2008526805A (ja) 2008-07-24
JP2008526805A5 JP2008526805A5 (OSRAM) 2009-02-05

Family

ID=36046933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007549866A Pending JP2008526805A (ja) 2005-01-11 2006-01-09 ベータ−２アドレナリン作動薬のケイヒ酸塩

Country Status (15)

Country Link
US (2) US7772250B2 (OSRAM)
EP (1) EP1846374A1 (OSRAM)
JP (1) JP2008526805A (OSRAM)
KR (1) KR20070097106A (OSRAM)
CN (1) CN101137625A (OSRAM)
AU (1) AU2006205933A1 (OSRAM)
BR (1) BRPI0606712A2 (OSRAM)
CA (1) CA2594484A1 (OSRAM)
EA (1) EA200701260A1 (OSRAM)
IL (1) IL184246A0 (OSRAM)
MA (1) MA29167B1 (OSRAM)
MX (1) MX2007008459A (OSRAM)
NO (1) NO20073282L (OSRAM)
NZ (1) NZ556335A (OSRAM)
WO (1) WO2006074897A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074897A1 (en) * 2005-01-11 2006-07-20 Glaxo Group Limited Cinnamate salts of a beta-2 adrenergic agonist
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
EP2064174B1 (en) 2006-08-10 2016-10-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Preparation of (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
WO2009154557A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
JP5837890B2 (ja) 2010-03-10 2015-12-24 アメリカ合衆国 神経膠芽腫および星状細胞腫の治療におけるフェノテロールおよびフェノテロール類似体の使用
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042164A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc Aryl aniline beta-2 adrenergic receptor agonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US694568A (en) * 1901-01-03 1902-03-04 James W Mccarthy Yarn or thread guide for spinning-machines.
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
EP0211595B1 (en) * 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
HU225869B1 (en) * 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
GB9700226D0 (en) * 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
EP1622875B1 (en) 2003-05-08 2009-12-02 Theravance, Inc. Crystalline forms of an arylaniline beta-2 adrenergic receptor agonist
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) * 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
US7317023B2 (en) * 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
WO2006074897A1 (en) * 2005-01-11 2006-07-20 Glaxo Group Limited Cinnamate salts of a beta-2 adrenergic agonist

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042164A1 (en) * 2001-11-13 2003-05-22 Theravance, Inc Aryl aniline beta-2 adrenergic receptor agonists

Also Published As

Publication number Publication date
US7772250B2 (en) 2010-08-10
EP1846374A1 (en) 2007-10-24
EA200701260A1 (ru) 2008-02-28
CN101137625A (zh) 2008-03-05
CA2594484A1 (en) 2006-07-20
MX2007008459A (es) 2007-07-25
NZ556335A (en) 2009-07-31
NO20073282L (no) 2007-09-04
MA29167B1 (fr) 2008-01-02
KR20070097106A (ko) 2007-10-02
US20080125462A1 (en) 2008-05-29
IL184246A0 (en) 2007-10-31
AU2006205933A1 (en) 2006-07-20
BRPI0606712A2 (pt) 2010-03-16
US20060189654A1 (en) 2006-08-24
WO2006074897A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
CN1910137B (zh) 用作β2肾上腺素能受体激动剂的芳基苯胺衍生物
JP4143413B2 (ja) β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
US7772434B2 (en) Crystalline form of a β2 adrenergic receptor agonist
US20050075271A1 (en) Crystalline beta2 adrenergic receptor agonist
US7060712B2 (en) Crystalline form of aryl aniline β2 adrenergic receptor agonist
JP2005533868A (ja) アリールエタノールアミンβ２−アドレナリン受容体アゴニスト化合物
US7772250B2 (en) Compounds
MXPA06003093A (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino.
JP2007514691A (ja) 呼吸器疾患を治療するためのベンゾチオフェンおよびチオクロメン含有フェネタノールアミン誘導体
EP1893580A1 (en) NOVEL SALT FORM OF A ß2 -ADRENERGIC AGONIST QUINOLIN-2-ONE DERIVATIVE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120821